BioSpace News Archive

Genetown

Biogen’s Aducanumab: A Look at the Drug’s History and Recent Updates

One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease.

March 26, 2021
·
6 min read
·
Mark Terry
Policy

Is the FDA Getting Tougher on Drug Applications?

There appears to be some evidence that the agency is cracking down in general, although there’s debate among analysts about what exactly is going on.

March 26, 2021
·
5 min read
·
Mark Terry
Drug Development

Clinical Catch-Up: March 22-26

There was a fair amount of clinical trial news last week. Here’s a look.

March 26, 2021
·
8 min read
·
Mark Terry
Policy

Report: Orphan Drug Act Boosted Rare Disease Therapies, But Access is Uneven

The Orphan Drug Act passed in 1983 and granted tax credits, subsidies and fee waivers for rare disease drug development in areas of unmet need. It also guaranteed seven years of market exclusivity following approval, longer than the five years typical for most new chemical entities.

March 26, 2021
·
2 min read
·
Mark Zipkin
Deals

Three Biopharma Companies Making Their Nasdaq Debut

This morning, Ikena Oncology, Design Therapeutics and Edgewise Therapeutics began trading on the exchange.

March 26, 2021
·
3 min read
·
Alex Keown
Policy

New COVID-19 Findings: Oral Transmission and the UK Variant’s Reproduction Rate

What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.

March 26, 2021
·
3 min read
·
Mark Terry
Biotech Bay

Gyroscope Eyes Clinical Success Against AMD with $148 Million in Series C

The financing involves Forbion’s Growth Opportunities Fund and includes its founding cornerstone investor, Syncona Investment Management Limited, which provided $42.3 million in investment.

March 26, 2021
·
2 min read
·
Kristiane Polido
Business

BMS CEO Earned $20 Million in 2020, a 7% Increase Amidst a Global Pandemic

In his fifth year as CEO, his take-home was about $20.15 million – an almost $1.7 million base pay plus $13.5 million in stock awards, with another $5 million in incentive plan pay with “other” pay.

March 26, 2021
·
3 min read
·
Kate Goodwin
FDA

FDA Action Alert: Merck, Aveo and Acadia

As this week’s FDA Action Alert emphasizes, not everything goes as planned with the U.S. FDA. With three PDUFA dates, two of them ran into issues. Read on to find out more.

March 26, 2021
·
3 min read
·
Mark Terry
Business

Novartis Closes Colorado Gene Manufacturing Site Two Years After Acquisition

In 2019, Novartis subsidiary AveXis announced it acquired a manufacturing facility in Colorado to provide additional production capacity for Zolgensma. Just two years later, the facility will be closed and 400 people will be without a job.

March 26, 2021
·
2 min read
·
Alex Keown